Biotricity Inc.

BTCY Healthcare Medical Devices

Biotricity Inc.’s revenue for fiscal 2026 (year ended March 2026) was $16.0 million, up 16.0% from fiscal 2025.

Revenue
+10.4%
EPS
−66.7%
Free cash flow
+235.8%
Total debt
+3.48%

Quarter to June 2026, against a year earlier

0.06 0.01 +20.00%
Market cap
$10.9M
P/E
0.0×
Fwd P/E
0.0×
Dividend yield
—
F-score
5/9
Altman Z
−33.34
Beneish M
−3.24
Dividend safety
n/a

Biotricity Inc. (BTCY) P/E ratio

Alert me on P/E ratio

Biotricity Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2026 0.0× —
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —

Quarterly newest first

Period P/E ratio Change
Jun 2026 0.0× —
Mar 2026 0.0× —
Dec 2025 0.0× —
Sep 2025 0.0× —
29 more quarters

Against its own ten years

Low 0.0× High 0.0×
Ten-year median 0.0×
Current reading's percentile 100

P/E ratio against peers

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on BTCY